Please check your internet connection and try again.
# Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep
## Overview
Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep is a combination antiviral medication containing ledipasvir and sofosbuvir used for the treatment of chronic hepatitis C virus (HCV) infection.
## Primary Indications
Treatment of chronic hepatitis C virus (HCV) infection in adults and pediatric patients. Specific genotypes and treatment durations depend on prior treatment history and presence of cirrhosis.
## Adult Dosing
The standard dose is one tablet (ledipasvir 90 mg/sofosbuvir 400 mg) taken orally once daily for 8, 12, or 24 weeks, depending on HCV genotype, prior treatment, and presence of cirrhosis. Refer to specific treatment guidelines for precise duration.
## Pediatric Dosing
Ledipasvir/sofosbuvir is approved for pediatric patients 12 years of age and older, weighing at least 35 kg. The dose is one tablet (ledipasvir 90 mg/sofosbuvir 400 mg) taken orally once daily for 12 or 24 weeks, depending on HCV genotype and prior treatment history.
## Dose Adjustments
No dose adjustment is required for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment; data is limited. No dose adjustment is required for renal impairment.
## Contraindications
* Hypersensitivity to ledipasvir, sofosbuvir, or any component of the formulation.
* Concurrent use with strong P-glycoprotein (P-gp) inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort).
## Adverse Effects
Common adverse effects include headache, fatigue, nausea, diarrhea, and insomnia.
## Key Drug Interactions
* **Strong P-gp inducers:** Concurrent use significantly reduces ledipasvir and sofosbuvir concentrations, potentially leading to loss of efficacy. Avoid coadministration.
* **Antacids (containing magnesium or aluminum hydroxide):** May decrease absorption of ledipasvir. Separate administration by at least 4 hours.
* **Certain antiretrovirals:** May require dose adjustments or monitoring for potential drug-drug interactions.
## Monitoring
* HCV viral load (RNA) to assess treatment response and confirm sustained virologic response (SVR) post-treatment.
* Liver function tests.
* Renal function.
* Consider monitoring for bradycardia if coadministered with amiodarone.
## Clinical Pearls
* Treatment duration is guided by specific HCV genotype and patient factors, often determined by local protocol.
* SVR is defined as undetectable HCV RNA 12 weeks after completion of therapy.
* Hepatitis B virus (HBV) reactivation has been reported in patients treated with direct-acting antivirals (DAAs). Screen for prior HBV infection before initiating therapy.
***
**Disclaimer:** This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions.
